Five ways to treat ED.
One that treats the cause.

A non-invasive cardiovascular therapy that uses pneumatic cuffs around the legs and hips, inflating in sync with the heartbeat to push blood backward up the arterial tree. Standard course is 35 one-hour sessions over 7 weeks. FDA-cleared for cardiac conditions; off-label for ED with RCT evidence.

"Treats the underlying endothelial dysfunction that causes most ED. Effects measured in months, not hours. The only option that simultaneously reduces cardiovascular risk."

The dominant pharmaceutical class for ED. These drugs block the enzyme that breaks down cGMP, extending the effect of nitric oxide and allowing arteries that can dilate to dilate longer. Generally safe and effective for most men with mild-to-moderate vasculogenic ED.

"Excellent symptom override. Doesn't fix anything; doesn't claim to. The right tool for situational use while addressing the underlying biology through other means."

Restores testosterone in men with documented low levels. Can improve libido, energy, mood, and erectile function in the genuinely hypogonadal — but does relatively little for ED in men with normal-range testosterone. Carries cardiovascular considerations that require monitoring.

"The right answer for low-T. The wrong answer for the much larger group of men with normal testosterone and vascular ED."

Acoustic waves applied directly to the penis with the aim of stimulating angiogenesis and tissue regeneration locally. Evidence is suggestive but mixed; the strongest published results are for men with mild-to-moderate vasculogenic ED. Does not address systemic cardiovascular disease.

"Targets the local tissue rather than the systemic vasculature. Some men benefit significantly. Best for men without significant cardiovascular disease who want a local intervention."

Mechanical and pharmacological options for men in whom oral medications don't work or are contraindicated. Injections produce reliable erections through direct vascular smooth muscle relaxation; vacuum devices produce erections by negative pressure. Neither addresses the underlying disease.

"Reliable rescue tools. Nobody wants to be on them, but they work when needed. The appropriate fallback when other options have been exhausted."

No — there is no reason to stop. EECP has no drug interactions with PDE5 inhibitors. Many men use both in parallel: EECP to improve the underlying vascular biology, and a PDE5 inhibitor on hand for on-demand use during and after treatment. The two approaches are complementary, not competing.

EECP does not directly raise testosterone levels. If labs confirm genuine hypogonadism (low T), testosterone replacement therapy addresses a hormonal cause that EECP does not. However, improving cardiovascular health, sleep quality, and autonomic balance through EECP can support hormonal function. The two are not mutually exclusive.

Shockwave therapy targets local penile tissue regeneration. EECP targets systemic vascular function. For men with primarily local tissue damage and no significant cardiovascular disease, shockwave therapy may be the more targeted option. For men with cardiovascular risk factors alongside their ED, EECP addresses both simultaneously. Some men benefit from both.

PDE5 inhibitor failure is often a sign that nitric oxide production has fallen below the threshold where extending its action makes a difference. This is a strong argument for EECP — which works to restore nitric oxide production rather than extend what little remains. Men who have failed PDE5 inhibitors are often the best EECP candidates.

The key question is: what is the primary cause of your ED? If it's vascular (most men over 50), EECP addresses the root cause. If it's hormonal (low T confirmed by labs), TRT is the primary intervention. If it's primarily psychological, behavioral therapy is most appropriate. Most men benefit from addressing multiple factors in parallel rather than trying one thing at a time.

EECP is covered by Medicare and most private insurers for FDA-approved indications (refractory angina, certain heart failure cases), but not for ED alone. Men who qualify for EECP on cardiac grounds — and who also have ED — often receive the vascular benefit under their cardiac coverage.

PDE5 inhibitors last 4–36 hours per dose. Shockwave therapy results last months to ~2 years. TRT requires continuous use. EECP results typically last 3–5 years per course, with some men reporting sustained benefit beyond that. A second course can be repeated if symptoms return.